世界病毒学杂志(英文版)最新文献

{"title":"Possible agent for COVID-19 treatment: Rifampicin.","authors":"Ozlem Celik Aydin, Sonay Aydın, Sureyya Barun","doi":"10.5501/wjv.v11.i5.391","DOIUrl":"10.5501/wjv.v11.i5.391","url":null,"abstract":"<p><p>Rifampicin is a promising drug for the treatment of coronavirus disease 2019 based on its antiviral properties and recent <i>in silico</i> studies. <i>In silico</i> studies can serve as a foundation for further studies.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 5","pages":"391-393"},"PeriodicalIF":0.0,"publicationDate":"2022-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0e/3f/WJV-11-391.PMC9523331.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40391950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortality rate of COVID-19 infection in end stage kidney disease patients on maintenance hemodialysis: A systematic review and meta-analysis.","authors":"Ivan Cancarevic,&nbsp;Mahmoud Nassar,&nbsp;Ahmed Daoud,&nbsp;Hatem Ali,&nbsp;Nso Nso,&nbsp;Angelica Sanchez,&nbsp;Avish Parikh,&nbsp;Asma Ul Hosna,&nbsp;Bhavana Devanabanda,&nbsp;Nazakat Ahmed,&nbsp;Karim M Soliman","doi":"10.5501/wjv.v11.i5.352","DOIUrl":"https://doi.org/10.5501/wjv.v11.i5.352","url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19) has been the most talked-about disease of the past few years. Patients with significant comorbidities have been at particular risk of adverse outcomes. This study looked at the outcomes and risk factors for adverse outcomes among patients on chronic hemodialysis for end-stage renal disease, a group of patients known to be particularly susceptible to infectious complications.</p><p><strong>Aim: </strong>To assess outcomes and risk factors for adverse outcomes of COVID-19 infection among patients on chronic hemodialysis.</p><p><strong>Methods: </strong>We searched PubMed/MEDLINE, EMBASE, <i>Reference Citation Analysis</i> (https://www.referencecitationanalysis.com/) and Web of Science databases for relevant terms and imported the results into the Covidence platform. From there, studies were assessed in two stages for relevance and quality, and data from studies that satisfied all the requirements were extracted into a spreadsheet. The data was then analyzed descriptively and statistically.</p><p><strong>Results: </strong>Of the 920 studies identified through the initial database search, only 17 were included in the final analysis. The studies included in the analysis were mostly carried out during the first wave. We found that COVID-19 incidence among patients on hemodialysis was significant, over 10% in some studies. Those who developed COVID-19 infection were most likely going to be hospitalized, and over 1 in 5 died from the infection. Intensive care unit admission rate was lower than the infection lethality rate. Biochemical abnormalities and dyspnea were generally reported to be associated with adverse outcomes.</p><p><strong>Conclusion: </strong>This systematic review confirms that patients on chronic hemodialysis are very high-risk individuals for COVID-19 infections, and a significant proportion was infected during the first wave. Their prognosis is overall much worse than in the general population, and every effort needs to be made to decrease their exposure.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 5","pages":"352-361"},"PeriodicalIF":0.0,"publicationDate":"2022-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6d/01/WJV-11-352.PMC9523330.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40390402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of COVID-19 with hepatic metabolic dysfunction.","authors":"Ramesh Kumar,&nbsp;Vijay Kumar,&nbsp;Rahul Arya,&nbsp;Utpal Anand,&nbsp;Rajeev Nayan Priyadarshi","doi":"10.5501/wjv.v11.i5.237","DOIUrl":"https://doi.org/10.5501/wjv.v11.i5.237","url":null,"abstract":"<p><p>The coronavirus disease 2019 (COVID-19) pandemic continues to be a global problem with over 438 million cases reported so far. Although it mostly affects the respiratory system, the involvement of extrapulmonary organs, including the liver, is not uncommon. Since the beginning of the pandemic, metabolic com-orbidities, such as obesity, diabetes, hypertension, and dyslipidemia, have been identified as poor prognostic indicators. Subsequent metabolic and lipidomic studies have identified several metabolic dysfunctions in patients with COVID-19. The metabolic alterations appear to be linked to the course of the disease and inflammatory reaction in the body. The liver is an important organ with high metabolic activity, and a significant proportion of COVID-19 patients have metabolic comorbidities; thus, this factor could play a key role in orchestrating systemic metabolic changes during infection. Evidence suggests that metabolic dysregulation in COVID-19 has both short- and long-term metabolic implications. Furthermore, COVID-19 has adverse associations with metabolic-associated fatty liver disease. Due to the ensuing effects on the renin-angiotensin-aldosterone system and ammonia metabolism, COVID-19 can have significant implications in patients with advanced chronic liver disease. A thorough understanding of COVID-19-associated metabolic dysfunction could lead to the identification of important plasma biomarkers and novel treatment targets. In this review, we discuss the current understanding of metabolic dysfunction in COVID-19, focusing on the liver and exploring the underlying mechanistic pathogenesis and clinical implications.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 5","pages":"237-251"},"PeriodicalIF":0.0,"publicationDate":"2022-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/6e/WJV-11-237.PMC9523326.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40390403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 and hemolysis, elevated liver enzymes and thrombocytopenia syndrome in pregnant women - association or causation?","authors":"Prashant Nasa,&nbsp;Deven Juneja,&nbsp;Ravi Jain,&nbsp;Ruchi Nasa","doi":"10.5501/wjv.v11.i5.310","DOIUrl":"https://doi.org/10.5501/wjv.v11.i5.310","url":null,"abstract":"<p><p>Pregnant women are among the high-risk population for severe coronavirus disease 2019 (COVID-19) with unfavorable peripartum outcomes and increased incidence of preterm births. Hemolysis, the elevation of liver enzymes, and low platelet count (HELLP) syndrome and severe preeclampsia are among the leading causes of maternal mortality. Evidence supports a higher odd of pre-eclampsia in women with COVID-19, given overlapping pathophysiology. Involvement of angiotensin-converting enzyme 2 receptors by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for the entry to the host cells and its downregulation cause dysregulation of the renin-angiotensin-aldosterone system. The overexpression of Angiotensin II mediated <i>via</i> p38 Mitogen-Activated Protein Kinase pathways can cause vasoconstriction and uninhibited platelet aggregation, which may be another common link between COVID-19 and HELLP syndrome. On PubMed search from January 1, 2020, to July 30, 2022, we found 18 studies on of SARS-COV-2 infection with HELLP Syndrome. Most of these studies are case reports or series, did not perform histopathology analysis of the placenta, or measured biomarkers linked to pre-eclampsia/HELLP syndrome. Hence, the relationship between SARS-CoV-2 infection and HELLP syndrome is inconclusive in these studies. We intend to perform a mini-review of the published literature on HELLP syndrome and COVID-19 to test the hypothesis on association <i>vs</i> causation, and gaps in the current evidence and propose an area of future research.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 5","pages":"310-320"},"PeriodicalIF":0.0,"publicationDate":"2022-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6f/69/WJV-11-310.PMC9523323.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40390406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anatomophysiological relationships and clinical considerations of taste and smell loss in patients with COVID-19.","authors":"Maria Fernanda Rossi Vigliar,&nbsp;Karina Torres Pomini,&nbsp;Daniela Vieira Buchaim,&nbsp;Rogerio Leone Buchaim","doi":"10.5501/wjv.v11.i5.362","DOIUrl":"https://doi.org/10.5501/wjv.v11.i5.362","url":null,"abstract":"<p><strong>Background: </strong>There are numerous conflicting discussions about the outbreak of the new coronavirus 2019 (COVID-19).</p><p><strong>Aim: </strong>To present some anatomical and physiological considerations about two of the symptoms reported by patients: The loss or reduction of smell and taste.</p><p><strong>Methods: </strong>The loss or reduction of smell and taste is presented in a peculiar way, with some cases of persistence even after COVID-19. For this, it was searched in three databases, PubMed/MEDLINE, Web of Science, and Scopus, using the following keywords: \"Smell\", \"Taste\", \"Smell AND COVID-19\", \"Taste AND COVID-19\", with no publication time restriction, only in English with full text available, excluding also brief communications, letters to the editor, editorials, reviews, comments, and conference abstracts.</p><p><strong>Results: </strong>The search found 776 articles in the PubMed/MEDLINE database, 1018 in the Web of Science database, and 552 in the Scopus database, from which duplicates were removed (104 articles). Finally, 17 studies were selected for detailed analysis within the eligibility criteria, with titles and abstracts related to central nervous system lesions responsible for smell and taste. This review suggests that viral mechanisms of action may be related to lesions both at the local level and at the level of the central nervous system, lasting up to 3 to 4 wk. It is considered persistent if it exceeds this period, as reported in one case in this review. There are still few studies about the treatment, and among those addressed in this review, only two studies reported possible treatments and emphasized the scarcity of data, with the best option being treatments that do not cause harm, such as gustatory and olfactory physiotherapy.</p><p><strong>Conclusion: </strong>Given the scarcity of data, this review emphasizes the importance of prevention, through the correct use of personal protective equipment by health professionals and respect for local behavioral indications. It is also emphasized, through five studies, that there is a predominance of such symptoms in patients with COVID-19, which can be a tool to control dissemination, through the early isolation of patients until the results are ready.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 5","pages":"362-374"},"PeriodicalIF":0.0,"publicationDate":"2022-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/af/fd/WJV-11-362.PMC9523329.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40390404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of high dose vitamin C in management of hospitalised COVID-19 patients: A minireview.","authors":"Deven Juneja,&nbsp;Anish Gupta,&nbsp;Sahil Kataria,&nbsp;Omender Singh","doi":"10.5501/wjv.v11.i5.300","DOIUrl":"https://doi.org/10.5501/wjv.v11.i5.300","url":null,"abstract":"<p><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as one of the most dreadful viruses the mankind has witnessed. It has caused world-wide havoc and wrecked human life. In our quest to find therapeutic options to counter this threat, several drugs have been tried, with varying success. Certain agents like corticosteroids, some anti-virals and immunosuppressive drugs have been found useful in improving clinical outcomes. Vitamin C, a water-soluble vitamin with good safety profile, has been tried to reduce progression and im-prove outcomes of patients with coronavirus disease 2019 (COVID-19). Because of its anti-oxidant and immunomodulatory properties, the role of vitamin C has expanded well beyond the management of scurvy and it is increasingly been employed in the treatment of critically ill patients with sepsis, septic shock, acute pancreatitis and even cancer. However, in spite of many case series, observational studies and even randomised control trials, the role of vitamin C remains ambiguous. In this review, we will be discussing the scientific rationale and the current clinical evidence for using high dose vitamin C in the management of COVID-19 patients.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 5","pages":"300-309"},"PeriodicalIF":0.0,"publicationDate":"2022-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7a/6f/WJV-11-300.PMC9523318.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40390407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute kidney injury and electrolyte disorders in COVID-19.","authors":"Gabriel Martins Nogueira,&nbsp;Noel Lucas Oliveira Rodrigues Silva,&nbsp;Ana Flávia Moura,&nbsp;Marcelo Augusto Duarte Silveira,&nbsp;José A Moura-Neto","doi":"10.5501/wjv.v11.i5.283","DOIUrl":"https://doi.org/10.5501/wjv.v11.i5.283","url":null,"abstract":"<p><p>Acute kidney injury (AKI) and electrolyte disorders are important complications of hospitalized coronavirus disease 2019 (COVID-19) patients. AKI is thought to occur due to multiple pathophysiological mechanisms, such as multiple organ dysfunction (mainly cardiac and respiratory), direct viral entry in the renal tubules, and cytokine release syndrome. AKI is present in approximately one in every ten hospitalized COVID-19 patients. The incidence rates of AKI increase in patients who are admitted to the intensive care unit (ICU), with levels higher than 50%. Additionally, renal replacement therapy (RRT) is used in 7% of all AKI cases, but in nearly 20% of patients admitted to an ICU. COVID-19 patients with AKI are considered moderate-to-severe cases and are managed with multiple interdisciplinary conducts. AKI acts as a risk factor for mortality in severe acute respiratory syndrome coronavirus 2 infection, especially when RRT is needed. Electrolyte disorders are also common manifestations in hospitalized COVID-19 patients, mainly hyponatremia, hypokalemia, and hypocalcemia. Hyponatremia occurs due to a combination of syndrome of inappropriate secretion of antidiuretic hormone and gastrointestinal fluid loss from vomiting and diarrhea. When it comes to hypokalemia, its mechanism is not fully understood but may derive from hyperaldosteronism due to renin angiotensin aldosterone system overstimulation and gastrointestinal fluid loss as well. The clinical features of hypokalemia in COVID-19 are similar to those in other conditions. Hypocalcemia is the most common electrolyte disorder in COVID-19 and seems to occur because of vitamin D deficiency and parathyroid imbalance. It is also highly associated with longer hospital and ICU stay.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 5","pages":"283-292"},"PeriodicalIF":0.0,"publicationDate":"2022-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/1e/WJV-11-283.PMC9523327.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40392628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of cardiac bioenzymes in predicting cardiovascular outcomes in SARS-CoV-2.","authors":"Anjani Muthyala, Sandeep Sasidharan, Kevin John John, Amos Lal, Ajay K Mishra","doi":"10.5501/wjv.v11.i5.375","DOIUrl":"10.5501/wjv.v11.i5.375","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular complications have been increasingly recognized in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) associated coronavirus disease 2019 (COVID-19). Cardiac biomarkers are released because of this ongoing cardiovascular injury and can act as surrogate markers to assess the disease severity.</p><p><strong>Aim: </strong>To review the variation and utility of these biomarkers in COVID-19 to ascertain their role in diagnosis, prognosis and clinical outcomes of the disease.</p><p><strong>Methods: </strong>We performed a literature search in PubMed, Medline and the Reference Citation Analysis (RCA), using the search terms \"COVID-19\" and \"cardiac bioenzymes\" or \"cardiac biomarkers\". Additionally, we also used the latest reference citation analysis tool to identify more articles.</p><p><strong>Results: </strong>Cardiac troponin has been consistently elevated in patients with COVID-19 associated myocarditis, and strongly correlated with adverse prognosis. Natri-uretic peptides including brain natriuretic peptide (BNP) and pro-BNP is elevated in patients with COVID-19 associated cardiac injury, irrespective of their prior heart failure status, and independently correlated with worst outcomes. Alongside these traditional biomarkers, novel cardiac bioenzymes including presepsin, soluble ST2 and copeptin, are also increasingly recognized as markers of cardiovascular injury in COVID-19 and can be associated with poor outcomes.</p><p><strong>Conclusion: </strong>Assessment of cardiac bioenzymes at admission and their serial monitoring can help assess the severity of disease and predict mortality in patients with SARS-CoV-2 infection. Future studies are needed to elude the critical importance of novel biomarkers.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 5","pages":"375-390"},"PeriodicalIF":0.0,"publicationDate":"2022-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/17/cc/WJV-11-375.PMC9523328.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40390405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rhino-orbital-cerebral mucormycosis as a complication of coronavirus disease 2019.","authors":"Raid M Al-Ani","doi":"10.5501/wjv.v11.i5.293","DOIUrl":"https://doi.org/10.5501/wjv.v11.i5.293","url":null,"abstract":"<p><p>Coronavirus disease 2019 is a highly contagious respiratory disease caused by severe acute respiratory syndrome coronavirus 2. This disease as well as its various treatments like steroids, antivirals, and antibacterials can alter the immune state of the affected individuals and result in secondary infections such as mucormycosis. Mucormycosis is a well-known opportunistic fungal infection that affects immunocompromised subjects, particularly those with diabetes mellitus, prolonged antibiotic or steroid use, and patients with organ trans-plantation, neutropenia, and hematological malignancies. Rhino-orbital-cerebral mucormycosis is an aggressive disease owing to its ability to invade the blood vessels by fungal hyphae, leading to necrosis of the involved structures. Large cases were reported from India, indicating that this clinical entity shows a geographical variation. The affected patients are suffering on a clinical spectrum depending on the stage of the disease. Radiological assessment, including computerized tomography and magnetic resonance imaging, is necessary to evaluate the stage of the disease and choose the appropriate surgical treatment. A multidisciplinary approach is required to treat rhino-orbital-cerebral mucor-mycosis and includes local or intravenous antifungal drugs, debridement of the dead tissues, and appropriate management of any predisposing conditions. The disease has a very poor prognosis with a death rate of 50%. This review aimed to sum-marize the demographic and clinical risk factors, investigations, treatments, and outcomes of coronavirus disease 2019 patients with rhino-orbital-cerebral mucormycosis.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 5","pages":"293-299"},"PeriodicalIF":0.0,"publicationDate":"2022-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6c/1a/WJV-11-293.PMC9523325.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40390408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Manifestations of COVID-19 infection in children with malignancy: A single-center experience in Jordan.","authors":"Mousa Ahmad Qatawneh,&nbsp;Moath Altarawneh,&nbsp;Ruba Alhazaimeh,&nbsp;Mais Jazazi,&nbsp;Omaiema Jarrah,&nbsp;Alaa Shorman,&nbsp;Laila Alsadah,&nbsp;Maher Mustafa","doi":"10.5501/wjv.v11.i5.321","DOIUrl":"https://doi.org/10.5501/wjv.v11.i5.321","url":null,"abstract":"<p><strong>Background: </strong>The coronavirus disease 2019 (COVID-19) has been the cause of a global health crisis since the end of 2019. All countries are following the guidelines and re-commendations released by the World Health Organization to decrease the spread of the disease. Children account for only 3%-5% of COVID-19 cases. Few data are available regarding the clinical course, disease severity, and mode of treatment in children with malignancy and COVID-19.</p><p><strong>Aim: </strong>To evaluate the treatment plan and outcome of children with malignancy who contracted COVID-19.</p><p><strong>Methods: </strong>A retrospective study of the medical files of patients with malignancy who contracted COVID-19 between July 2020 and June 2021 was performed. The following data were reviewed for all patients: primary disease, laboratory data, admission ward, clinical status upon admission, disease course, treatment plan, and outcome. Eligible patients were those with malignancy who tested positive for COVID-19 by reverse transcription polymerase chain reaction.</p><p><strong>Results: </strong>A total of 40 patients who had malignancy contracted COVID-19 from July 1, 2020 to June 1, 2021. Their primary diseases were as follows: 34 patients (85%) had hematological malignancies (30 had acute lymphoblastic leukemia, 2 had acute myeloblastic leukemia, and 2 had Hodgkin lymphoma), whereas 6 patients (15%) had solid tumors (2 had neuroblastoma, 2 had rhabdomyosarcoma, and 2 had central nervous system tumors). Twelve patients (30%) did not need hospitalization and underwent home isolation only, whereas twenty-eight patients (70%) required hospitalization (26 patients were admitted in the COVID-19 ward and 2 were admitted in the pediatric intensive care unit).</p><p><strong>Conclusion: </strong>COVID-19 with malignancy in the pediatric age group has a benign course and does not increase the risk of having severe infection compared to other children.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 5","pages":"321-330"},"PeriodicalIF":0.0,"publicationDate":"2022-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/20/WJV-11-321.PMC9523322.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40392629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}